A5015083623- Virus-based gene therapy research
- interferon and immune responses
- Glioma Diagnosis and Treatment
- Cancer Research and Treatments
- Microfluidic and Bio-sensing Technologies
- Cancer Cells and Metastasis
- CAR-T cell therapy research
- Cytomegalovirus and herpesvirus research
- Spectroscopy and Quantum Chemical Studies
- Lysosomal Storage Disorders Research
- RNA Interference and Gene Delivery
- Gold and Silver Nanoparticles Synthesis and Applications
- Liver physiology and pathology
- Cholangiocarcinoma and Gallbladder Cancer Studies
University of Massachusetts Chan Medical School
2015-2018
University of Calcutta
2009
GM2 gangliosidoses, including Tay-Sachs disease and Sandhoff disease, are lysosomal storage disorders caused by deficiencies in β-N-acetylhexosaminidase (Hex). Patients afflicted primarily with progressive central nervous system (CNS) dysfunction. Studies mice, cats, sheep have indicated safety widespread distribution of Hex the CNS after intracranial vector infusion AAVrh8 vectors encoding species-specific α- or β-subunits at a 1:1 ratio. Here, study was conducted cynomolgus macaques (cm),...
The highly invasive property of glioblastoma ( GBM ) cells and genetic heterogeneity are largely responsible for tumor recurrence after the current standard‐of‐care treatment thus a direct cause death. Previously, we have shown that intracranial interferon‐beta IFN ‐β) gene therapy by locally administered adeno‐associated viral vectors AAV successfully treats noninvasive orthotopic models. Here, extend these findings testing this approach in human xenograft syngeneic mouse First, show single...
Complete surgical removal of all glioblastoma (GBM) cells is impossible due to extensive infiltration into brain parenchyma that ultimately leads tumor recurrence. The current standard care affords modest improvements in survival. New therapeutic interventions are needed prevent Local AAV-hIFNβ gene delivery the was previously shown eradicate noninvasive orthotopic U87 tumors mice. However, widespread CNS may be necessary treat invasive GBMs. Here we investigated effectiveness systemically...
Introduction: Glioblastoma multiforme (GBM) is the most prevalent primary brain tumor, with a median survival (MS) of only 14.6 months from diagnosis despite providing multimodal treatment including maximal surgical resection, radiation and chemotherapy. Due to highly invasive properties GBM cells, complete resection practically impossible, leading tumor recurrence death. Thus, new approaches are needed prevent recurrence. IFNb pleiotropic cytokine potent anti-tumor effects. Previous studies...
Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor. The current standard-of-care treatment including surgery, radiation temozolomide (TMZ) chemotherapy does not prolong survival satisfactorily. Here we have tested feasibility, efficacy safety of a potential gene therapy approach using AAV as delivery vehicle for GBM. Interferon-beta (IFNβ) cytokine molecule also having pleiotropic anticancerous properties. Previously it has been shown by our group that...